In addition to the IPASS findings, there have been six randomized controlled phase III trials comparing EGFR TKIs (gefitinib, erlotinib or afatinib) to chemotherapy in EGFR-mutant lung cancer patients, both in Asian and Caucasian populations (Table 1). The gene discussed is EGFR; the disease is lung cancer.